Digital Health Platform Achieves SOC 2 Milestone in Booming Sector

1. Rocket Doctor is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000. 
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor.
3. Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1 Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, Rocket Doctor has paid Street Smart, an affiliate of Streetwise Reports, US$2,500
2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts.  The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

The digital health sector continues to attract significant attention from investors as technology transforms how patients access care. Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) recently announced that its wholly owned digital health platform and marketplace, Rocket Doctor Inc., has achieved SOC 2 Type I compliance following an independent third-party audit that evaluated its security, privacy, and operational controls. This development positions the company for potential enterprise opportunities at a time when healthcare organizations prioritize verified security standards.

Digital Health Market Expands Rapidly With AI Adoption

According to a July 12 report from Grand View Research, the global digital health market was valued at US$347.4 billion in 2025 and was estimated to reach US$420.2 billion in 2026. The firm projected the market would grow to US$1.83 trillion by 2033 at a compound annual growth rate of 23.4%. Grand View Research stated that the market is driven by several factors, such as a strong domestic digital health market for telehealth platform developers, mHealth app providers, wearable device manufacturers, and e-prescription systems. North America remains the largest regional contributor, accounting for 37.1% of global revenue in 2025. Software holds the largest component segment share at 45.7%, while telehealthcare leads technology segments at 44.7%.

Also on July 12, Tracxn reported that the global HealthTech sector included approximately 145,000 companies, with 26,800 funded companies that had collectively raised US$384 billion in venture capital and private equity. The research firm stated, This sector includes companies providing digital health solutions for disease management, diagnosis, treatment, etc. It also noted that the sector encompassed both B2B and B2C software, platforms, and connected devices for providers, hospitals, consumers, employers, and the life science industry. Tracxn reported that the HealthTech sector had produced 964 initial public offerings and approximately 5,230 acquisitions, while total funding reached US$14.5 billion during 2026 to date.

According to a July 13 report by Heather Landi in Fierce Healthcare, digital health companies raised US$7.4 billion across 244 venture capital deals during the first half of 2026, compared with US$6.4 billion during the same period a year earlier. Investment increasingly concentrates in larger financings, with 20 megadeals of US$100 million or more accounting for 45% of capital invested.

Rocket Doctor AI Strengthens Enterprise Readiness Through SOC 2 Type I

Rocket Doctor AI said the certification further underscores the company's commitment to maintaining security, privacy, and operational standards while protecting sensitive patient and partner information. According to the company, SOC 2 Type I is a framework developed by the American Institute of Certified Public Accountants (AICPA) to evaluate how organizations protect sensitive customer data. The independent audit assessed Rocket Doctor's controls over an extended period and verified that its security, availability, confidentiality, and privacy practices are designed and operating effectively. The examination reviewed its information security and access management practices, data privacy and confidentiality controls, incident response and business continuity planning, risk management and governance processes, and secure system development and change management procedures. Rocket Doctor AI stated that the audit demonstrated that these controls are properly designed and implemented across the organization.

Rocket Doctor AI said it has invested in governance, cybersecurity infrastructure, risk management, and compliance programs since the platform's inception and dedicated substantial resources over the past eight months toward achieving SOC 2 Type I compliance as part of its broader enterprise growth strategy. As healthcare increasingly relies on digital infrastructure, data security and compliance have become baseline requirements for technology adoption, said Harry Cherniak, cofounder, Chief Privacy Officer, and COO of Rocket Doctor Inc., in a company news release. Achieving SOC 2 Type I compliance validates the rigorous controls and processes we've built to safeguard patient and partner data. This milestone provides healthcare organizations, employers, payors, pharmacies, and government partners with independent assurance that Rocket Doctor meets the highest standards for security and operational integrity.

Key Investor Takeaways

• Rocket Doctor AI achieved SOC 2 Type I compliance, providing independent verification of its security and privacy controls for enterprise partners.
• The digital health market is projected to reach US$1.83 trillion by 2033, supported by rising telehealth and AI adoption.
• The company's AI-powered platform has delivered more than 750,000 patient visits across Canada and is expanding into U.S. states.
• Analyst Stewart Thomson assigned a Strong Speculative Buy rating with long-term price targets up to CA$1.60.
• Insider ownership stands at 4.29% while the company maintains a market capitalization of CA$59.50 million.
• Expansion plans target additional U.S. states, including Florida and Texas, alongside new payer relationships.

Physician-Built AI Platform Offers Differentiated Approach

Rocket Doctor AI said it is continuing to expand its healthcare services across North America through its physician-built, AI-powered healthcare platform. The company stated that its proprietary Global Library of Medicine (GLM) is a clinically validated decision support system developed with input from hundreds of physicians worldwide, while Rocket Doctor Inc. operates an AI-powered digital health platform and marketplace. According to the company's July 2026 investor presentation, Rocket Doctor's platform has supported more than 750,000 patient visits through a network of more than 350 physicians across Alberta, British Columbia, and Ontario, while expanding operations in California, Maryland, and New York through payer partnerships. The investor presentation also states that the company is pursuing additional U.S. state expansion, including Florida and Texas, while extending existing relationships with payers. It reports in-network patient access of 9,875,993 in New York, 8,126,637 in California, and 3,180,599 in Maryland.

Rocket Doctor AI's investor presentation further states that the company has 16 clinically active U.S. physicians, 46 physicians in the credentialing process, and MD capacity pending, which it describes as three times current levels. The platform connects patients with board-certified healthcare providers who can diagnose, treat, and manage a wide range of health concerns while supporting 20 other specialties. Virtual appointments are designed to provide high-quality care that is comparable to in-person visits.

Technical Analyst Saw AI Healthcare Platform Building Momentum With Strong Speculative Buy Rating

¹In a March 17 report, technical analyst Stewart Thomson discussed Rocket Doctor AI Inc. and described the company as committed to empowering both physicians and patients with access to personalized healthcare regardless of who they are, where they are, or what their lifestyle brings. He wrote that the company's AI platform is designed by doctors, so doctors who use it get exactly what they need, and that its digital health platform and marketplace help to make healthcare more accessible and efficient, especially for those in rural communities. Thomson stated that Rocket Doctor's technology is dedicated to transforming healthcare by empowering patients, providers, and healthcare systems through advances in technology, adding that the approach is centered on enhancing provider capabilities, not replacing clinical decisions.

From a technical perspective, Thomson assigned Rocket Doctor AI a Strong Speculative Buy technical rating and identified a short-term technical price target of CA$0.80, a medium-term technical price target of CA$1.00, and a long-term technical price target of CA$1.60. Building a successful digital health practice in the U.S. is hard; competitors face a minimum of 18 to 24+ months to replicate the position Rocket Doctor AI is in today, technology, payer contracts, credentialing, and revenue ops...with no guarantee of success, Thomson wrote.

Ownership and Share Structure

²Insider ownership of Rocket Doctor AI totals 4.29%. Retail investors hold the rest. Rocket Doctor AI has 99.16 million shares outstanding. Its market cap is CA$59.50M. Its 52-week range is CA$0.33-0.98/share.

Common Questions from Investors

What is SOC 2 Type I compliance? SOC 2 Type I is a security framework that evaluates whether an organization's controls for security, availability, confidentiality, and privacy are properly designed at a point in time.

How large is the digital health market? Grand View Research estimates the global digital health market will reach US$1.83 trillion by 2033, growing at 23.4% annually.

What does the company's AI platform do? Rocket Doctor AI operates a physician-built platform that supports virtual care, smart triage, remote monitoring, and clinical decision support through its Global Library of Medicine.

What analyst rating did the company receive? Technical analyst Stewart Thomson assigned Rocket Doctor AI a Strong Speculative Buy rating with targets up to CA$1.60 long term.

Rocket Doctor AI continues to focus on scaling its secure, compliant platform amid favorable industry tailwinds. Retail investors should review the company's latest filings and consider both the growth potential and execution risks typical of early-stage healthcare technology firms.